{"url_path":"/sec/mltx/8-k/2026-06-22/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1821586/0001213900-26-070362-index.html","accession_number":"0001213900-26-070362","cik":"0001821586","ticker":"MLTX","issuer_name":"MoonLake Immunotherapeutics","edgar_url":"https://www.sec.gov/Archives/edgar/data/1821586/0001213900-26-070362-index.html","primary_entity_key":"0001821586","primary_entity_name":"MoonLake Immunotherapeutics"},"word_count":185,"has_tables":true,"body_markdown":"**Item 7.01. Regulation FD Disclosure.**\n\n** **\n\nOn June 21, 2026, MoonLake Immunotherapeutics\n(the “Company”) issued a press release announcing the Week 52 results from its Phase 3 VELA clinical trials (VELA-1 and VELA-2)\nevaluating the efficacy and safety of the Nanobody® sonelokimab (“SLK”) in adult patients with moderate-to-severe hidradenitis\nsuppurativa (“HS”), as well as an interim analysis of its Phase 3 VELA-TEEN trial in adolescents with HS. The Company is hosting\na webcast today, Monday, June 22, 2026 at 8:00 am, Eastern Time, to discuss the data results.\n\n \n\nA copy of the press release and the webcast presentation\nare furnished as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K and are incorporated by reference herein.\nThe exhibits furnished under Item 7.01 of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of\nSection 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference\nin any filing under the Exchange Act or the Securities Act, regardless of any general incorporation language in such filing."}